Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-22-098941
Filing Date
2022-09-09
Accepted
2022-09-09 17:00:44
Documents
1
Period of Report
2022-09-07

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2225460-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2225460-1_4seq1.xml 4 4379
  Complete submission text file 0001104659-22-098941.txt   6010
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560
Business Address
Boudes Pol F (Reporting) CIK: 0001454771 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 221236747